KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Intangibles (2016 - 2025)

Pfizer (PFE) has disclosed Intangibles for 14 consecutive years, with $64.9 billion as the latest value for Q4 2023.

  • On a quarterly basis, Intangibles rose 49.64% to $64.9 billion in Q4 2023 year-over-year; TTM through Dec 2023 was $64.9 billion, a 49.64% increase, with the full-year FY2023 number at $64.9 billion, up 49.64% from a year prior.
  • Intangibles was $64.9 billion for Q4 2023 at Pfizer, up from $43.4 billion in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $64.9 billion in Q4 2023 to a low of $25.1 billion in Q4 2021.
  • A 5-year average of $38.4 billion and a median of $34.2 billion in 2019 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: fell 19.51% in 2020, then skyrocketed 72.47% in 2022.
  • Pfizer's Intangibles stood at $35.4 billion in 2019, then dropped by 19.51% to $28.5 billion in 2020, then dropped by 11.68% to $25.1 billion in 2021, then surged by 72.47% to $43.4 billion in 2022, then surged by 49.64% to $64.9 billion in 2023.
  • Per Business Quant, the three most recent readings for PFE's Intangibles are $64.9 billion (Q4 2023), $43.4 billion (Q4 2022), and $25.1 billion (Q4 2021).